Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-08-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations and related company disclosures. It includes statements about the company's verification of information, risk warnings, and references to previous announcements and regulatory actions. The document does not contain financial statements or detailed financial data, nor is it a full report like an annual or interim report. It is a regulatory announcement about stock trading and company status, including risk factors and compliance with disclosure rules. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-08-19 Chinese
关于公司及相关当事人收到《行政处罚决定书》的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the receipt of an administrative penalty decision from the China Securities Regulatory Commission (CSRC). It details the investigation, findings of violations related to information disclosure, penalties imposed on the company and individuals, and the company's response and risk disclosures. The document does not contain financial statements or detailed financial data but is a regulatory announcement about legal and compliance matters. It fits the category of a Legal Proceedings Report (LTR) as it updates on significant regulatory actions involving the company.
2025-08-15 Chinese
关于董事会、监事会延期换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the postponement of the board of directors and supervisory board re-election. It discusses the extension of the current board and management terms to ensure continuity and stability, referencing relevant company law and regulations. There is no financial data, no mention of a report being attached or published, and the content focuses on board/management changes and governance matters. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is clearly an announcement about management changes, not a full report or other filing type.
2025-07-25 Chinese
关于累计诉讼事项的公告
Legal Proceedings Report Classification · 100% confidence The document is a detailed announcement from 广州市香雪制药股份有限公司 regarding cumulative litigation matters over a twelve-month period. It includes extensive tables listing lawsuits involving the company and its subsidiaries as defendants and plaintiffs, with case types, progress, and amounts involved. The document references compliance with Shenzhen Stock Exchange listing rules and discloses litigation amounts relative to audited net assets. It explicitly states that the company has disclosed major litigation in its 2024 Annual Report and other announcements, and that no undisclosed major litigation exists. The document is a standalone announcement focused on legal proceedings and litigation updates, not a full annual report, audit report, or financial statement. It is not a brief notice or a certification but a substantive legal proceedings update. Therefore, it fits the category of Legal Proceedings Report (LTR).
2025-07-18 Chinese
关于收到延长预重整期间决定书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the receipt of a court decision to extend the pre-restructuring period. It details the progress of the pre-restructuring process, including court decisions, appointment of interim managers, and related legal and financial procedures. The document is a formal disclosure about ongoing legal and financial restructuring activities, including risk warnings and regulatory compliance notes. It does not contain financial statements or detailed financial analysis, nor is it a transcript, presentation, or voting result. It is primarily a regulatory announcement about the company's restructuring status and related legal proceedings. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 2131 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-07-10 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2024 Annual General Meeting (AGM) resolutions of 广州市香雪制药股份有限公司. It details the meeting date, voting methods, attendance, and the voting results on various proposals including the 2024 annual report, financial statements, board and supervisory reports, remuneration, and other corporate matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full annual report or financial statements themselves. It includes legal opinions confirming the validity of the meeting and voting process. The document length is about 5690 characters, which is consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-06-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.